Diaz Monica M, Caylor Jacob, Strigo Irina, Lerman Imanuel, Henry Brook, Lopez Eduardo, Wallace Mark S, Ellis Ronald J, Simmons Alan N, Keltner John R
Department of Neurology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States.
Department of Anesthesiology, University of California, San Diego, San Diego, CA, United States.
Front Pain Res (Lausanne). 2022 May 11;3:869215. doi: 10.3389/fpain.2022.869215. eCollection 2022.
Chronic pain affects ~10-20% of the U.S. population with an estimated annual cost of $600 billion, the most significant economic cost of any disease to-date. Neuropathic pain is a type of chronic pain that is particularly difficult to manage and leads to significant disability and poor quality of life. Pain biomarkers offer the possibility to develop objective pain-related indicators that may help diagnose, treat, and improve the understanding of neuropathic pain pathophysiology. We review neuropathic pain mechanisms related to opiates, inflammation, and endocannabinoids with the objective of identifying composite biomarkers of neuropathic pain. In the literature, pain biomarkers typically are divided into physiological non-imaging pain biomarkers and brain imaging pain biomarkers. We review both types of biomarker types with the goal of identifying composite pain biomarkers that may improve recognition and treatment of neuropathic pain.
慢性疼痛影响着约10%-20%的美国人口，估计每年花费6000亿美元，是迄今为止所有疾病中最重大的经济成本。神经性疼痛是一种特别难以治疗的慢性疼痛，会导致严重残疾和生活质量低下。疼痛生物标志物为开发客观的疼痛相关指标提供了可能性，这些指标可能有助于诊断、治疗神经性疼痛并增进对其病理生理学的理解。我们综述了与阿片类药物、炎症和内源性大麻素相关的神经性疼痛机制，目的是识别神经性疼痛的复合生物标志物。在文献中，疼痛生物标志物通常分为生理性非成像疼痛生物标志物和脑成像疼痛生物标志物。我们对这两类生物标志物进行综述，目的是识别可能改善神经性疼痛识别和治疗的复合疼痛生物标志物。
